Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ImmunityBio, Inc. entered into Stock Purchase Agreement with Nant Capital, LLC, NantMobile, LLC, NantCancerStemCell, LLC valued at approximately $270 million in aggregate principal amount (effective 2023-09-11).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Nant Capital, LLC, NantMobile, LLC, NantCancerStemCell, LLC
- Value
- approximately $270 million in aggregate principal amount
- Effective
- 2023-09-11
Exact text from the filing
Also on September 11, 2023, the Company, the Company’s wholly-owned subsidiary NantCell, Inc., Nant Capital, NantMobile, LLC (“NantMobile”) and NantCancerStemCell, LLC (“NCSC” and together with Nant Capital and NantMobile, the “Purchasers”), entered into a Stock Purchase Agreement (the “SPA”) pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the “Notes,” representing approximately $270 million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of 209,291,936 shares of Common Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ImmunityBio, Inc. entered into $200.0 million Convertible Promissory Note with Nant Capital, LLC valued at $200.0 million (effective 2023-09-11).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- Nant Capital, LLC
- Value
- $200.0 million
- Effective
- 2023-09-11
Exact text from the filing
On September 11, 2023, ImmunityBio, Inc. (the “Company”) executed a $200.0 million convertible promissory note with Nant Capital, LLC (“Nant Capital” or the “Investor”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ImmunityBio, Inc. amended a notes offering with Nant Capital, LLC valued at approximately $535 million (effective 2023-09-11).
- Action
- amendment
- Agreement
- notes offering
- Counterparty
- Nant Capital, LLC
- Value
- approximately $535 million
- Effective
- 2023-09-11
Exact text from the filing
Also on September 11, 2023, the Company and Nant Capital entered into a series of letter agreements pursuant to which the maturity dates of certain existing promissory notes with an aggregate principal amount of approximately $535 million entered into between the Company and Nant Capital were each extended from December 31, 2023 to December 31, 2024.
View on SEC.gov